Your AI investments aren't adding up. Here's why.

Most health plan technology leaders follow a familiar playbook for enterprise AI: identify the highest-priority workflow, find the best tool for that singular function, deploy, measure, and repeat. It's a logical approach, but it's also why so many organizations end up with a fragmented portfolio of siloed tools, a governance framework rebuilt from scratch with every new deployment, and an AI that gets harder to manage the more they add to it.

A sequencing strategy that makes every investment build on the last is the foundation of enterprise AI that actually scales. Here's what that looks like in practice.

Enterprise AI has a compounding problem

Without a cohesive AI strategy, every new deployment becomes its own isolated initiative–requiring teams to rebuild data models, integrations, and governance processes from the ground up. 

The alternative is sequencing that compounds in value. When each AI deployment is built on a shared clinical context layer–where the intelligence produced in one workflow is available to the next–the cost of expansion declines and the value of each new use case increases. What prior authorization learns, payment integrity can use. What appeals surfaces, utilization management can learn from. The foundation gets stronger with every addition, rather than wider and more fragmented.

This is what separates an AI portfolio from a true intelligence layer–a distinction that hinges on the sequencing decisions made at the very beginning.

Start where the clinical intelligence is richest

The first deployment in an enterprise AI strategy is the most consequential. It establishes the data foundation, validates the governance model, and sets the precedent for how AI capabilities will scale. A misstep here constrains the entire architecture built on top of it.

The highest-value starting points share a few characteristics:

• High volume and well-defined scope: Use cases where AI performance can be measured against a clear standard, and where decision volume is sufficient to validate results efficiently.
• Rich in unstructured clinical data: Prior authorization is a prime example of a process that combines clinical documentation, policy interpretation, and medical-necessity reasoning–information that can be reused across a wide range of downstream functions.
• Deployable within existing infrastructure: The first deployment should demonstrate value inside current systems, not require replacing them.

Expand where the intelligence already flows

The second phase of sequencing is about finding the functions where the intelligence from phase one is already most useful. 

From prior authorization, several natural adjacencies emerge:

• Payment integrity: Clinically trained AI applied to UM findings and clinical documentation collected upstream enables more precise audit claim selection downstream–raising hit rates and recovery yield without building a new data foundation.
• Appeals: Existing clinical evidence and policy logic from prior authorization are reused rather than recreated, accelerating reviews and improving consistency across the organization.
• Quality and Stars performance: Clinical documentation captured during UM review workflows unlocks evidence trapped in unstructured data, enabling direct gap closure into HEDIS engines, and supporting Star measure performance without separate chart retrieval.

Each expansion is faster, more cost-effective, and more impactful than the last, because it builds on existing intelligence, rather than creating it from scratch.

Govern from day one, not deployment three

The most common sequencing mistake isn't selecting the wrong first use case–it's treating governance as an afterthought.

Organizations that scale AI successfully establish their governance model before the first deployment goes live–defining where human oversight is required, what accuracy thresholds must be met before expanding AI responsibility, and how performance will be monitored in production. That model spans the entire AI portfolio, rather than being rebuilt for each new use case. Each new deployment benefits from the validation infrastructure established for the last, meaning trust and capability grow together. Expanding AI responsibility becomes a deliberate operational decision, not an unintentional drift.

What are you building toward with your AI investments?

Every deployment either extends a connected intelligence foundation or adds another isolated tool to manage. Clearly distinguishing this before committing to a vendor or workflow separates health plans that achieve operational coherence from those that merely accumulate AI tools. 

Looking to build an enterprise AI sequencing strategy for your health plan? Our guide–Facing operational reality: A leader's guide to building connected intelligence across the health plan–walks through how to evaluate platforms, sequence investments, and build the connected intelligence foundation that turns AI ambition into operational results.

Download the guide